Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2), also known as Prostaglandin D2 receptor 2 (DP2), is a G protein-coupled receptor that mediates the chemotaxis of Th2 lymphocytes, eosinophils, and basophils toward inflammatory sites upon binding its primary ligand Prostaglandin D2 (PGD2). Activation leads to increased intracellular calcium levels, reduced cyclic AMP levels, and activation of signaling pathways, resulting in recruitment and activation of Th2-type immune cells during allergic inflammation. CRTH2 plays a central role in mediating allergic inflammation and is a therapeutic target for diseases like severe eosinophilic asthma. Antagonists targeting CRTH2 are under clinical development.
Antagonism of CRTH2 receptor, blocking PGD2-mediated signaling
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2).